Cardiovascular disease (CVD) is the world's major concern affecting the heart, blood arteries, and the blood that flows through and between them, making it a significant obstacle to contemporary healthcare practices. Approximately one in three individuals has a CVD, and many of them have several, overlapping diseases that might eventually result in catastrophic events such as a heart attack or stroke. The previous century opened the door for progress of life-saving drugs and treatment modalities. Recent developments in nanomaterials provide novel approaches for the treatment of CVD. Due to their unique properties, which include increased target specificity, sensitivity, and both active and passive targeting of cardiac tissues, the use of nanoparticles as carriers has received a lot of attention in the field of cardiology. Drug delivery using heart-targeted nanocarriers is a safe, efficient method of treating heart-related conditions such as hypertension, atherosclerosis, and myocardial infarction. Here, we highlight significant clinical opportunities in the quickly emerging field of CVD nanomedicine. This review concentrates on the use of nanoparticle-based therapeutics in CVD and provides a key take away regarding the use of metal, lipid, and polymer-based nanoparticle in CVD treatment. In this review, we emphasize recent advances in the use of nanomedicine to treat CVD and the therapeutic potential of drug delivery via nanoparticles in clinical prospects.
Keywords: Cardiac tissue; Cardiovascular; Disease; Drug delivery; Nanoparticle.
Copyright © 2025. Published by Elsevier Ltd.
